Evaluation of Topical Application of BMX-010 in Subjects With Rosacea

Exclusion Criteria

• •1. Any dermatological conditions on the face that could interfere with clinical evaluations;
• •2. Any underlying disease(s) or some other dermatological condition of the face that requires the use of interfering topical or systemic therapy or makes evaluations and lesion count inconclusive;
• •3. Presence of beard or excessive facial hair at Screening which would interfere with the study treatments or study assessments and refusal to remove for duration of study;
• •4. Subjects with any underlying disease that the Investigator deems uncontrolled, and poses a concern for the subject's safety while participating in the study;
• •5. Concomitant skin disease that could confound clinical evaluations or increase risk to the subject;
• •6. Use of medicated make-up (including anti-aging make-up) throughout the study;
• •7. Use during the study of 1) systemic steroids, 2) topical retinoids to the face, 3) antibiotics known to impact rosacea, 4) immunosuppressive agents, or immunomodulators;
• •8. Facial use of 1) topical steroids, 2) topical anti-inflammatory agents, 3) topical antimycotics, 4) any topical rosacea treatments or 4) topical antibiotics;
• •9. Use of medicated cleansers on the face (throughout the study);
• •10. Use of topical astringents or abrasives, medical topical preparations (prescription and OTC products) within 2 days prior to Baseline and throughout the study;
• •11. Systemic or skin infection requiring antimicrobial therapy;
• •12. Systemic chemotherapy or radiotherapy within 4 weeks of the Baseline Visit;
• •13. Immunocompromise of any cause, known human immunodeficiency virus infection, or acquired immunodeficiency syndrome;
• •14. Pregnancy, planned pregnancy, lactation, or inadequate contraception as judged by the investigator;
• •15. Active drug or alcohol dependence;
• •16. Significant acute or chronic medical, neurological, or psychiatric illness that, in the judgment of the investigator, could compromise subject safety, limit the subject's ability to complete the study, and/or compromise the objectives of the study;
• •17. Previous clinical trial participation for the indication being treated in this protocol.